Neurocrine Biosciences' Ingrezza Gets FDA Approval
19 August 2023 - 7:33AM
Dow Jones News
By Brenda León
Neurocrine Biosciences said Friday the Food and Drug
Administration approved Ingrezza capsules to treat adults with
chorea, an abnormal involuntary movement disorder associated with
Huntington's disease.
The San Diego-based biopharmaceutical company said the FDA
approval is supported by data from two clinical studies conducted
in collaboration with the Huntington Study Group.
Huntington's disease is a hereditary progressive
neurodegenerative disorder in which the loss of certain neurons
within the brain causes motor, cognitive and psychiatric
symptoms.
Most people with the disease experience chorea, which is
characterized by irregular and unpredictable movements. Chorea can
affect various parts of the body and interfere with motor
coordination, gait, swallowing and speech.
Huntington's disease affects an estimated 41,000 adults in the
U.S., with more than 200,000 at risk of inheriting the disease,
Neurocrine Biosciences said.
Write to Brenda León at brenda.leon@wsj.com
(END) Dow Jones Newswires
August 18, 2023 17:18 ET (21:18 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Neurocrine Biosciences (NASDAQ:NBIX)
Historical Stock Chart
From Apr 2024 to May 2024
Neurocrine Biosciences (NASDAQ:NBIX)
Historical Stock Chart
From May 2023 to May 2024
